People: DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

20 Jun 2018
Change (% chg)

€0.04 (+0.12%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Horner, George 

Mr. Georges F. Horner, III, started serving as Director of DBV Technologies S.A. on January 17, 2012 and resigned from this position as of June 22, 2018. He previously served as Chairman of the Board of the Company between December 23, 2010 and January 17, 2012. He joined the Company's Board on December 16, 2010. He is a biotech executive consultant for several private companies in the United States and Europe. Previous, he was CEO of Prestwick Pharmaceuticals, a CNS company that he directed to obtain FDA approval for Tetrabenazine (TBZ), a drug licensed in the United States to treat Huntington’s Disease patients. Prior to that, Mr. Horner was CEO of Vicuron Pharmaceuticals, an anti-infective company. Additionally, he has held numerous executive, general management, business development and marketing/sales positions with Abbott Laboratories and E.R. Squibb. Mr. Horner is Chairman of the Board of Creabilis Therapeutics of Luxembourg, Chairman of the Board of Omthera Pharmaceuticals of Bedminster, New Jersey, USA, and member of the Durata Therapeutics board of directors. He graduated from Belmont Abbey College with an AB degree.

Basic Compensation

Total Annual Compensation, EUR 15,000
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR --
Fiscal Year Total, EUR 15,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --